Investigational Drug Details
| Drug ID: | D362 |
| Drug Name: | TERN-101 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB16045 |
| DrugBank Description: | TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)). |
| PubChem ID: | 25204767 |
| CasNo: | 1103500-20-4 |
| Repositioning for NAFLD: | No |
| SMILES: | C(OC1CCN(CC1)c1cc2c(cc1)c(cn2C)C(=O)O)c1c(noc1C1CC1)c1c(Cl)cccc1Cl |
| Structure: |
|
| InChiKey: | RPVDFHPBGBMWID-UHFFFAOYSA-N |
| Molecular Weight: | 540.447 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FXR agonist |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 completed (NCT04328077) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0432 | NCT04328077 | Phase 2 | Not recruiting | No Results Available | 13/03/2020 | 17 August 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |